Home › Trial NCT04688931
A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
- Trial IDNCT04688931
- StatusTerminated
- PhasePhase 3
- Study typeInterventional
- SponsorUroGen Pharma Ltd.
- Enrollment282
- Start date2021-02-19
- ConditionsBladder Cancer · Urothelial Carcinoma · Urothelial Carcinoma Bladder
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.